Over half of all phase 3 clinical trials fail, with an estimated cost to a pharmaceutical company of between $800m to $1.4bn per drug failure. Only one in ten drugs make it through clinical trials to ...

For many healthtech innovators the real adoption challenge is not always in proving the clinical value of their product. It is overcoming structural barriers that stand in their way. So, let’s explore ...

Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, ...

Linda Bosserman, M.D., joined City of Hope in Los Angeles nine years ago as a medical oncologist specializing in breast cancer and value-based care. During her 26 years in private practice, prior to ...

From an interview conducted during Patient-Centered Oncology Care 2023. Collaboration between payers and providers is crucial for developing effective oncology care pathways, and at Tennessee Oncology ...

Preventing Future Harm: Identifying the Drivers of an Unsafe Discharge to Improve Safety on an Inpatient Oncology Service This study used claims and authorization data from a national insurer between ...

Artificial intelligence is rapidly transforming clinical medicine, with AI-powered tools increasingly being used for ...

Human epidermal growth factor receptor 2 (HER2) is a membrane-spanning receptor that belongs to the family of epidermal growth factor receptor tyrosine kinases (EGFR TKIs), which consists of three ...